Research programme: Dicer-substrate siRNA therapeutics - Dicerna

Drug Profile

Research programme: Dicer-substrate siRNA therapeutics - Dicerna

Alternative Names: CTNNB1 DsiRNA; DCR BCAT; DCR-HBV; DCR-HBVS; DCR-PCSK9; Dicer siRNA - Dicerna; DsiRNA - Dicerna; DsiRNA-EX conjugate - Dicerna; GalNAc-DsiRNA-EX conjugates; GalXC therapy

Latest Information Update: 04 Apr 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Dicerna Pharmaceuticals
  • Class Antihyperglycaemics; Antihyperlipidaemics; Antineoplastics; Antirheumatics; Antivirals; Small interfering RNA
  • Mechanism of Action RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Haematological malignancies; Hepatitis B; Hypercholesterolaemia
  • Research Liver disorders
  • No development reported Solid tumours
  • Discontinued Hepatitis C; Hyperlipidaemia; Rheumatoid arthritis; Type 2 diabetes mellitus

Most Recent Events

  • 08 Aug 2018 Dicerna announces intention to submit regulatory applications for clinical trials in Australia and New Zealand in the fourth quarter of 2018
  • 20 Apr 2018 Dicerna Pharmaceuticals intends to submit IND or CTA for Unknown indication, in the second half of 2018
  • 20 Apr 2018 Dicerna Pharmaceuticals plans a clinical trial for Unknown indication in the second half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top